S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.18 (+0.00%)
AAPL   115.75 (-0.96%)
MSFT   214.89 (+0.04%)
FB   278.12 (-0.22%)
GOOGL   1,606.66 (+1.30%)
AMZN   3,176.40 (-0.27%)
TSLA   425.79 (+0.75%)
NVDA   534.44 (-1.21%)
BABA   306.28 (-0.55%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   54.38 (+2.01%)
AMD   79.42 (+0.28%)
T   28.28 (+5.84%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   60.67 (+0.76%)
NFLX   485.23 (-0.78%)
BA   169.07 (+3.18%)
NIO   27.38 (-1.72%)
DIS   127.56 (+0.73%)
S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.18 (+0.00%)
AAPL   115.75 (-0.96%)
MSFT   214.89 (+0.04%)
FB   278.12 (-0.22%)
GOOGL   1,606.66 (+1.30%)
AMZN   3,176.40 (-0.27%)
TSLA   425.79 (+0.75%)
NVDA   534.44 (-1.21%)
BABA   306.28 (-0.55%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   54.38 (+2.01%)
AMD   79.42 (+0.28%)
T   28.28 (+5.84%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   60.67 (+0.76%)
NFLX   485.23 (-0.78%)
BA   169.07 (+3.18%)
NIO   27.38 (-1.72%)
DIS   127.56 (+0.73%)
S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.18 (+0.00%)
AAPL   115.75 (-0.96%)
MSFT   214.89 (+0.04%)
FB   278.12 (-0.22%)
GOOGL   1,606.66 (+1.30%)
AMZN   3,176.40 (-0.27%)
TSLA   425.79 (+0.75%)
NVDA   534.44 (-1.21%)
BABA   306.28 (-0.55%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   54.38 (+2.01%)
AMD   79.42 (+0.28%)
T   28.28 (+5.84%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   60.67 (+0.76%)
NFLX   485.23 (-0.78%)
BA   169.07 (+3.18%)
NIO   27.38 (-1.72%)
DIS   127.56 (+0.73%)
S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.18 (+0.00%)
AAPL   115.75 (-0.96%)
MSFT   214.89 (+0.04%)
FB   278.12 (-0.22%)
GOOGL   1,606.66 (+1.30%)
AMZN   3,176.40 (-0.27%)
TSLA   425.79 (+0.75%)
NVDA   534.44 (-1.21%)
BABA   306.28 (-0.55%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   54.38 (+2.01%)
AMD   79.42 (+0.28%)
T   28.28 (+5.84%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   60.67 (+0.76%)
NFLX   485.23 (-0.78%)
BA   169.07 (+3.18%)
NIO   27.38 (-1.72%)
DIS   127.56 (+0.73%)
Log in
NASDAQ:CMRX

Chimerix Stock Forecast, Price & News

$2.73
+0.01 (+0.37 %)
(As of 10/22/2020 12:00 AM ET)
Add
Compare
Today's Range
$2.64
Now: $2.73
$2.82
50-Day Range
$2.30
MA: $2.65
$3.03
52-Week Range
$1.19
Now: $2.73
$3.88
Volume276,669 shs
Average Volume638,540 shs
Market Capitalization$169.81 million
P/E RatioN/A
Dividend YieldN/A
Beta1.79
Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include dociparstat sodium (DSTAT), a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of key proteins implicated in the retention and viability of acute myeloid leukemia blasts and leukemic stem cells in the bone marrow during chemotherapy; and brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications; and University of Michigan to research, develop, manufacture, and commercialize various products. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
Read More
Chimerix logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.51 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CMRX
CUSIPN/A
Phone919-806-1074
Employees43

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.52 million
Book Value$1.79 per share

Profitability

Net Income$-112,580,000.00
Net Margins-859.64%

Miscellaneous

Market Cap$169.81 million
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$2.73
+0.01 (+0.37 %)
(As of 10/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Chimerix (NASDAQ:CMRX) Frequently Asked Questions

How has Chimerix's stock been impacted by COVID-19?

Chimerix's stock was trading at $1.44 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CMRX stock has increased by 89.6% and is now trading at $2.73.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Chimerix?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Chimerix
.

When is Chimerix's next earnings date?

Chimerix is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Chimerix
.

How were Chimerix's earnings last quarter?

Chimerix, Inc. (NASDAQ:CMRX) released its earnings results on Monday, August, 10th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.17) by $0.01. The biopharmaceutical company earned $1.40 million during the quarter, compared to the consensus estimate of $1.17 million. Chimerix had a negative net margin of 859.64% and a negative return on equity of 31.42%.
View Chimerix's earnings history
.

What price target have analysts set for CMRX?

1 equities research analysts have issued 12 month target prices for Chimerix's shares. Their forecasts range from $7.00 to $7.00. On average, they anticipate Chimerix's share price to reach $7.00 in the next year. This suggests a possible upside of 156.4% from the stock's current price.
View analysts' price targets for Chimerix
.

Are investors shorting Chimerix?

Chimerix saw a decline in short interest during the month of September. As of September 15th, there was short interest totaling 851,300 shares, a decline of 17.3% from the August 31st total of 1,030,000 shares. Based on an average daily volume of 480,000 shares, the days-to-cover ratio is currently 1.8 days. Currently, 1.9% of the shares of the company are short sold.
View Chimerix's Short Interest
.

Who are some of Chimerix's key competitors?

What other stocks do shareholders of Chimerix own?

Who are Chimerix's key executives?

Chimerix's management team includes the following people:
  • Mr. Michael A. Sherman, CEO, Pres & Director (Age 54, Pay $869.4k)
  • Mr. Michael T. Andriole M.B.A., Chief Bus. Officer, Sec. & CFO (Age 47, Pay $539.79k)
  • Dr. Michael A. Alrutz, Sr. VP, Gen. Counsel & Corp. Sec. (Age 50, Pay $619.5k)
  • Mr. David Jakeman, Exec. Director of Fin. & Accounting and Principal Accounting Officer (Age 43)
  • Dr. Roy W. Ware Ph.D., MBA, Chief Manufacturing & Technology Officer
  • Dr. Randall Lanier Ph.D., Chief Science Officer
  • Ms. Michelle LaSpaluto, VP of Strategic Planning & Investor Relations
  • Dr. Allen S. Melemed M.B.A., M.D., Chief Medical Officer

What is Chimerix's stock symbol?

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

Who are Chimerix's major shareholders?

Chimerix's stock is owned by a variety of institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.09%). Company insiders that own Chimerix stock include David Jakeman, Fred A Middleton, Garrett Nichols, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer.
View institutional ownership trends for Chimerix
.

Which institutional investors are buying Chimerix stock?

CMRX stock was acquired by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have bought Chimerix stock in the last two years include Fred A Middleton, Martha J Demski, Michael A Sherman, Michael T Andriole, and Robert J Meyer.
View insider buying and selling activity for Chimerix
.

How do I buy shares of Chimerix?

Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Chimerix's stock price today?

One share of CMRX stock can currently be purchased for approximately $2.73.

How big of a company is Chimerix?

Chimerix has a market capitalization of $169.81 million and generates $12.52 million in revenue each year. The biopharmaceutical company earns $-112,580,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Chimerix employs 43 workers across the globe.

What is Chimerix's official website?

The official website for Chimerix is www.chimerix.com.

How can I contact Chimerix?

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected]

This page was last updated on 10/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.